A Phase 2 interventional study of brentuximab vedotin and cyclophosphamide in Peripheral T-cell Lymphoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Completed at 63 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, Peripheral — 3 open to participants now, 3 under way, 1 of them phase 3. Brentuximab Vedotin · Lymphoma, T-Cell, Peripheral.
Among the 11 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, Peripheral, this one is the 3rd largest by enrollment, is the only one that started in 2020, is one of 6 in phase 2, and was the 8th registered.
372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.
Browse Lymphoma, T-Cell, Peripheral studies →3 of the 11 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, Peripheral are open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
New York Medical College · Sites in United States
Ages 1–31
N.N. Petrov National Medical Research Center of Oncology
Ages 18–70
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 1
First in 2012; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is above the median of 44 across 328 interventional studies indexed under Lymphoma, T-Cell, Peripheral.
Median enrollment 33 across the 11 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen, a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.
Pfizer has 8 studies filed under Lymphoma, T-Cell, Peripheral — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, Peripheral, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following non-sALCL PTCL subtypes are eligible:
Exclusion Criteria
Current diagnosis of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with CD30 expression level \< 1%
Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: doxorubicin · Drug: prednisone
Participants with CD30 expression level ≥1% to \< 10%
Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: doxorubicin · Drug: prednisone
1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
Also known as: ADCETRIS
750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
100 mg daily administered orally on Days 1-5 of each cycle
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30 Assessment
ORR was defined as the percentage of participants with complete response (CR) or partial response (PR) following the completion of study treatment (at end of treatment \[EOT\]). CR and PR per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy and PR was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.
Time frame: At EOT or the first assessment after the last dose of study treatment (prior to long term follow-up or initiation of subsequent anti-cancer therapies); up to 41.91 months
Complete Response (CR) Rate Per BICR (Cheson 2007) by Central CD30 Assessment
CR rate was defined as the percentage of participants with CR following the completion of study treatment (at EOT). CR as per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.
Time frame: At EOT or the first assessment after the last dose of study treatment (prior to long term follow-up or initiation of subsequent anti-cancer therapies); up to 41.91 months
Progression Free Survival (PFS) Per BICR (Cheson 2007) by Central CD30 Assessment
PFS was defined as the time from start of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever came first. Kaplan-Meier method was used for analysis. PFS data was censored on the date of the last radiological assessment of measured lesions documenting absence of PD for participants without objective tumor progression and were still on study at the time of an analysis, were given antitumor treatment other than the study treatment or stem cell transplant (included donor lymphocyte infusion) or were removed from study prior to documentation of objective tumor progression. Participants who lacked an evaluation of tumor response after their first dose had their event time censored at 1 day.
Time frame: From the first dose of study treatment to first documentation of objective tumor progression or death due to any cause or censoring, whichever came first (approximately 61.7 months)
Overall Survival (OS) by Central CD30 Assessment
OS was defined as the time from first dose to death due to any cause. Participant not known to have died by the end of study follow-up, observation of OS was censored on the date the participants were last known to be alive (i.e., date of last contact). Participants who lacked data beyond the day of first dose had their survival time censored on the date of first dose (i.e., OS duration of 1 day). Kaplan-Meier method was used for analysis.
Time frame: From the first dose of study treatment until death or censoring date, whichever came first (approximately 61.7 months)
Duration of Response (DOR) Per BICR (Cheson 2007) by Central CD30 Assessment
DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (per Cheson 2007) or death, whichever came first. Participants without progression or death were censored. DOR was only calculated for the subset of participants achieving a CR or PR. CR and PR per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy and PR was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. Kaplan-Meier method was used for analysis.
Time frame: From the first documented CR or PR until the first documentation of tumor progression, death or censoring date, whichever came first (up to 61.7 months)
ORR Per BICR by Modified Lugano Criteria (Cheson 2014) by Central CD30 Assessment
ORR was defined as the percentage of participants with CR or PR following the completion of study treatment (at EOT) according to the modified Lugano criteria (Cheson 2014). Complete response was defined as complete disappearance of radiologic evidence of disease and PR was defined as at least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses.
Time frame: At EOT or the first assessment after the last dose of study treatment (prior to long term follow-up or initiation of subsequent anti-cancer therapies); up to 41.91 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment
An adverse event was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An adverse event was classified as a serious adverse event (SAE) if it met one of the following criteria: fatal, life threatening, hospitalization, disabling/incapacitating, congenital anomaly or birth defect or any medically significant event. TEAEs were events if they were newly occurring or worsen following study treatment. TESAE is any SAE that met treatment emergent definition. Treatment related AEs were which had evidence to suggest a causal relationship between the drugs and the adverse event, such as: an event that was uncommon and known to be strongly associated with drug exposure, an event that was not commonly associated with drug exposure but was otherwise uncommon in the population exposed to the drug. AEs included both SAEs and all non-SAEs.
Time frame: From first dose of the study treatment (Day 1) up to 30-37 days after the last dose of study treatment (approximately up to 6.6 months)
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment
Any Abnormal laboratory tests(Decreased values of hemoglobin,leukocytes,lymphocytes,neutrophils, platelets, calcium corrected for albumin,glomerular filtration rate estimated, glucose, phosphate, potassium,albumin,sodium and increased values of calcium corrected for albumin,creatinine, potassium, glucose, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, total Bilirubin, urate) that worsen from baseline were considered clinically significant by investigator.Abnormal test were recorded as AE if associated with accompanying symptoms,required additional diagnostic testing or medical/surgical intervention,study dosing change,study discontinuation,significant additional concomitant drug treatment,other therapy.As perNCI CTCAE grade(G)1:mild(asymptomatic or mild symptoms,clinical,diagnostic observations,no intervention),G2:moderate(minimal, local,noninvasive intervention),G3:severe,medically significant,G4:life-threatening,urgent intervention,G5:death related to AE
Time frame: From first dose of the study treatment (Day 1) up to 30-37 days after the last dose of study treatment (approximately up to 6.6 months)
Participants who had newly diagnosed non-systemic anaplastic large cell lymphoma (sALCL) peripheral T-cell lymphoma (PTCL) with \< 10% CD30 expression, were enrolled to receive A+CHP treatment (brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone). Enrollment was based on CD30 expression per local laboratory assessment. Analysis of efficacy outcome measures was based on CD30 expression per central laboratory assessment.
| Milestone | CD30 <1% [Local Laboratory Assessment] | CD30 1% to <10% [Local Laboratory Assessment] |
|---|---|---|
| Started | 34 | 48 |
| Completed | 0 | 0 |
| Not completed | 34 | 48 |
| Withdrew: Death | 10 | 13 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: In long term follow up | 22 | 34 |
ORR was defined as the percentage of participants with complete response (CR) or partial response (PR) following the completion of study treatment (at end of treatment \[EOT\]). CR and PR per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy and PR was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.
| Percentage of participants | CD30 <1% [Central Laboratory Assessment] | CD30 1% to <10% [Central Laboratory Assessment] |
|---|---|---|
| Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30 Assessment | 61 (38.5 to 80.3) | 81 (62.5 to 92.5) |
CR rate was defined as the percentage of participants with CR following the completion of study treatment (at EOT). CR as per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.
| Percentage of participants | CD30 <1% [Central Laboratory Assessment] | CD30 1% to <10% [Central Laboratory Assessment] |
|---|---|---|
| Complete Response (CR) Rate Per BICR (Cheson 2007) by Central CD30 Assessment | 52 (30.6 to 73.2) | 71 (52.0 to 85.8) |
PFS was defined as the time from start of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever came first. Kaplan-Meier method was used for analysis. PFS data was censored on the date of the last radiological assessment of measured lesions documenting absence of PD for participants without objective tumor progression and were still on study at the time of an analysis, were given antitumor treatment other than the study treatment or stem cell transplant (included donor lymphocyte infusion) or were removed from study prior to documentation of objective tumor progression. Participants who lacked an evaluation of tumor response after their first dose had their event time censored at 1 day.
Results for this outcome have not been posted.
OS was defined as the time from first dose to death due to any cause. Participant not known to have died by the end of study follow-up, observation of OS was censored on the date the participants were last known to be alive (i.e., date of last contact). Participants who lacked data beyond the day of first dose had their survival time censored on the date of first dose (i.e., OS duration of 1 day). Kaplan-Meier method was used for analysis.
Results for this outcome have not been posted.
DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (per Cheson 2007) or death, whichever came first. Participants without progression or death were censored. DOR was only calculated for the subset of participants achieving a CR or PR. CR and PR per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy and PR was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. Kaplan-Meier method was used for analysis.
Results for this outcome have not been posted.
ORR was defined as the percentage of participants with CR or PR following the completion of study treatment (at EOT) according to the modified Lugano criteria (Cheson 2014). Complete response was defined as complete disappearance of radiologic evidence of disease and PR was defined as at least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses.
| Percentage of participants | CD30 <1% [Central Laboratory Assessment] | CD30 1% to <10% [Central Laboratory Assessment] |
|---|---|---|
| ORR Per BICR by Modified Lugano Criteria (Cheson 2014) by Central CD30 Assessment | 57 (34.5 to 76.8) | 77 (58.9 to 90.4) |
An adverse event was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An adverse event was classified as a serious adverse event (SAE) if it met one of the following criteria: fatal, life threatening, hospitalization, disabling/incapacitating, congenital anomaly or birth defect or any medically significant event. TEAEs were events if they were newly occurring or worsen following study treatment. TESAE is any SAE that met treatment emergent definition. Treatment related AEs were which had evidence to suggest a causal relationship between the drugs and the adverse event, such as: an event that was uncommon and known to be strongly associated with drug exposure, an event that was not commonly associated with drug exposure but was otherwise uncommon in the population exposed to the drug. AEs included both SAEs and all non-SAEs.
| Participants | CD30 <1% [Local Laboratory Assessment] | CD30 1% to <10% [Local Laboratory Assessment] |
|---|---|---|
| TEAEs | 32 | 46 |
| TESAEs | 15 | 16 |
| Treatment related TEAEs | 25 | 40 |
Any Abnormal laboratory tests(Decreased values of hemoglobin,leukocytes,lymphocytes,neutrophils, platelets, calcium corrected for albumin,glomerular filtration rate estimated, glucose, phosphate, potassium,albumin,sodium and increased values of calcium corrected for albumin,creatinine, potassium, glucose, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, total Bilirubin, urate) that worsen from baseline were considered clinically significant by investigator.Abnormal test were recorded as AE if associated with accompanying symptoms,required additional diagnostic testing or medical/surgical intervention,study dosing change,study discontinuation,significant additional concomitant drug treatment,other therapy.As perNCI CTCAE grade(G)1:mild(asymptomatic or mild symptoms,clinical,diagnostic observations,no intervention),G2:moderate(minimal, local,noninvasive intervention),G3:severe,medically significant,G4:life-threatening,urgent intervention,G5:death related to AE
| Participants | CD30 <1% [Local Laboratory Assessment] | CD30 1% to <10% [Local Laboratory Assessment] |
|---|---|---|
| Hemoglobin decreased: Grade 1+2 | 19 | 34 |
| Hemoglobin decreased: Grade 3 | 3 | 1 |
| Leukocytes decreased: Grade 1+2 | 13 | 23 |
| Leukocytes decreased: Grade 3 | 4 | 5 |
| Leukocytes decreased: Grade 4 | 0 | 1 |
| Lymphocytes decreased: Grade 1+2 | 10 | 15 |
| Lymphocytes decreased: Grade 3 | 15 | 21 |
| Lymphocytes decreased: Grade 4 | 1 | 4 |
| Neutrophils decreased: Grade 1+2 | 3 | 12 |
| Neutrophils decreased: Grade 3 | 4 | 3 |
| Neutrophils decreased: Grade 4 | 1 | 3 |
| Platelets decreased: Grade 1+2 | 6 | 10 |
| Platelets decreased: Grade 4 | 0 | 1 |
| Calcium Corrected for Albumin increased: Grade 1+2 | 3 | 1 |
| Creatinine increased: Grade 1+2 | 19 | 30 |
| Glomerular Filtration Rate, Estimated decreased: Grade 1+2 | 2 | 4 |
| Glucose decreased: Grade 1+2 | 1 | 5 |
| Glucose increased: Grade 1+2 | 15 | 21 |
| Glucose increased: Grade 3 | 3 | 0 |
| Glucose increased: Grade 4 | 0 | 1 |
| Phosphate decreased: Grade 1+2 | 1 | 1 |
| Phosphate decreased: Grade 3 | 0 | 4 |
| Potassium decreased: Grade 1+2 | 2 | 5 |
| Potassium decreased: Grade 3 | 1 | 1 |
| Potassium decreased: Grade 4 | 0 | 1 |
| Alanine Aminotransferase increased: Grade 1+2 | 6 | 17 |
| Albumin decreased: Grade 1+2 | 3 | 8 |
| Alkaline Phosphatase increased: Grade 1+2 | 2 | 11 |
| Alkaline Phosphatase increased: Grade 3 | 2 | 0 |
| Aspartate Aminotransferase increased: Grade 1+2 | 8 | 15 |
| Aspartate Aminotransferase increased: Grade 3 | 0 | 1 |
| Calcium Corrected for Albumin decreased: Grade 1+2 | 2 | 2 |
| Potassium increased: Grade 1+2 | 2 | 4 |
| Potassium increased: Grade 3 | 1 | 0 |
| Sodium decreased: Grade 1+2 | 8 | 6 |
| Sodium decreased: Grade 3 | 1 | 3 |
| Sodium increased: Grade 1+2 | 0 | 2 |
| Total Bilirubin increased: Grade 1+2 | 1 | 1 |
| Urate increased: Grade 3 | 4 | 6 |
| Urate increased: Grade 4 | 2 | 0 |
Collected over Adverse events: From first dose of the study treatment (Day 1) maximum up to 30-37 days after the last dose of study treatment (approximately up to 6.6 months). All-cause mortality: throughout the study (up to 41 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD30 <1% [Local Laboratory Assessment] | 11/34 (32.4%) | 15/34 (44.1%) | 31/34 (91.2%) |
| CD30 1% to <10% [Local Laboratory Assessment] | 13/48 (27.1%) | 16/48 (33.3%) | 43/48 (89.6%) |
| Event | CD30 <1% [Local Laboratory Assessment] | CD30 1% to <10% [Local Laboratory Assessment] |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/34 | 9/48 |
| PyrexiaGeneral disorders | 4/34 | 1/48 |
| DiarrhoeaGastrointestinal disorders | 2/34 | 1/48 |
| FatigueGeneral disorders | 2/34 | 0/48 |
| AnaemiaBlood and lymphatic system disorders | 0/34 | 2/48 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/34 | 2/48 |
| PancytopeniaBlood and lymphatic system disorders | 1/34 | 0/48 |
| DysphagiaGastrointestinal disorders | 1/34 | 0/48 |
| EnteritisGastrointestinal disorders | 1/34 | 0/48 |
| Chest painGeneral disorders | 1/34 | 0/48 |
| Event | CD30 <1% [Local Laboratory Assessment] | CD30 1% to <10% [Local Laboratory Assessment] |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/34 | 19/48 |
| Peripheral sensory neuropathyNervous system disorders | 11/34 | 16/48 |
| AnaemiaBlood and lymphatic system disorders | 7/34 | 15/48 |
| NauseaGastrointestinal disorders | 8/34 | 14/48 |
| NeutropeniaBlood and lymphatic system disorders | 4/34 | 12/48 |
| PyrexiaGeneral disorders | 2/34 | 8/48 |
| AstheniaGeneral disorders | 5/34 | 3/48 |
| Oedema peripheralGeneral disorders | 5/34 | 6/48 |
| ConstipationGastrointestinal disorders | 3/34 | 7/48 |
| VomitingGastrointestinal disorders | 4/34 | 7/48 |
| Age, Continuous(Years) | CD30 <1% [Local Laboratory Assessment] | CD30 1% to <10% [Local Laboratory Assessment] | Total |
|---|---|---|---|
| Mean | 60.2 ± 11.3 | 61.0 ± 11.0 | 60.7 ± 11.1 |
| Sex: Female, Male(Participants) | CD30 <1% [Local Laboratory Assessment] | CD30 1% to <10% [Local Laboratory Assessment] | Total |
|---|---|---|---|
| Female | 10 | 26 | 36 |
| Male | 24 | 22 | 46 |
| Ethnicity (NIH/OMB)(Participants) | CD30 <1% [Local Laboratory Assessment] | CD30 1% to <10% [Local Laboratory Assessment] | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 10 | 19 |
| Not Hispanic or Latino | 22 | 34 | 56 |
| Unknown or Not Reported | 3 | 4 | 7 |
| Race (NIH/OMB)(Participants) | CD30 <1% [Local Laboratory Assessment] | CD30 1% to <10% [Local Laboratory Assessment] | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 26 | 37 | 63 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 5 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in May 2024, 41 months.
Results were first posted in May 2025, 1 year after primary completion.
Of 64 phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 96. This study's 41 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Lymphoma, T-Cell, Peripheral →
Seagen, a wholly owned subsidiary of Pfizer →